| Description | ELOVL1-IN-1 (1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide) is an ELOVL1 inhibitor. ELOVL1-IN-1 can reduce the levels of very long chain fatty acids. ELOVL1-IN-1 can be used in the study of adrenoleukodystrophy (ALD). |
| In vitro | 给予1 nM-10 μM ELOVL1-IN-1处理48小时，能够降低肾上腺脑白质营养不良（ALD）患者成纤维细胞和健康人成纤维细胞、ALD患者B淋巴细胞以及人类微胶质细胞中的长链脂肪酸（VLCFA）和溶血磷脂酰胆碱（LPC）的水平[1]。 |
| In vivo | 口服ELOVL1-IN-1能够显著降低ABCD1基因敲除小鼠（0.5-64 mg/kg；28天）、正常型（WT）大鼠（30-300 mg/kg；7天）和猕猴（30 mg/kg；7天）血液中的长链脂肪酸（VLCFA）水平，具体是C26:0 LPC水平[1]。 |
| Synonyms | 1-(2-Fluorophenyl)-N-(1-(2-fluoropyridin-4-YL)-1H-pyrazol-3-YL)cyclopropane-1-carboxamide |
| molecular weight | 340.33 |
| Molecular formula | C18H14F2N4O |
| CAS | 2227482-41-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 50 mg/mL (146.92 mM) |
| References | 1. Charifson PS, et, al. 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels. WO2018107056A1. |